Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 77 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Human Albumin Infusion Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome

NCT00617864
View directory record Official record
Conditions
Ovarian Hyperstimulation Syndrome
Interventions
Human Albumin Infusion, Saline Infusion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 42 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 11, 2026, 4:30 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211
View directory record Official record
Conditions
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
30
States / cities
Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 11, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion

NCT01951729
View directory record Official record
Conditions
Pre-diabetes
Interventions
Control, Xenin-25 without atropine, GIP without atropine, Placebo with atropine, Xenin-25 with atropine, GIP with atropine, GIP plus Xenin-25 without atropine, GIP plus Xenin-25 with atropine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 11, 2026, 4:30 PM EDT
Active, not recruiting Phase 1 Interventional

E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults

NCT04057833
View directory record Official record
Conditions
Rotator Cuff Tears, Muscle Atrophy or Weakness, Tendon Rupture - Shoulder, Safety Issues
Interventions
E-CEL UVEC
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 11, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)

NCT00684021
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 11, 2026, 4:30 PM EDT
Completed Phase 1Phase 2 Interventional

Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.

NCT03265808
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
allogeneic human mesenchymal stem cells (allo-hMSCs), Placebo
Drug
Lead sponsor
Ihsan M Salloum, MD, MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Harlingen, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 11, 2026, 4:30 PM EDT
Completed Early Phase 1 Interventional

u-STOP LVAD Bleed: Utilization of Umbilical Cord Lining Stem Cells (ULSCs) To Prevent Left Ventricular Assist Device (LVAD) Associated Angiodysplastic Bleeding

NCT04811261
View directory record Official record
Conditions
Angiodysplastic Bleeding
Interventions
Intravenous Infusion of UCLSCs
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Sep 11, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hemin in Healthy Subjects

NCT00882804
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Hemin infusion, placebo infusion
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2009 · Synced Sep 11, 2026, 4:30 PM EDT
Active, not recruiting Phase 1 Interventional

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

NCT04061746
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Mesenchymal Stem Cells (MSCs), Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)
Biological · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 11, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

NCT00220779
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Sep 11, 2026, 4:30 PM EDT
Recruiting Phase 2 Interventional

Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

NCT04476901
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
allogeneic human mesenchymal stem cells (hMSCs), Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Stanford, California • Miami, Florida • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 11, 2026, 4:30 PM EDT
Terminated Phase 1 Interventional Results available

Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer

NCT00006046
View directory record Official record
Conditions
Colorectal Cancer
Interventions
monoclonal antibody hu3S193
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 11, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease

NCT02600130
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Longeveron Mesenchymal Stem Cells, Placebo
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Delray Beach, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 11, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants

NCT00606437
View directory record Official record
Conditions
Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors, Hodgkin's Disease, Myelofibrosis
Interventions
Total Body Irradiation with Fludarabine in UCB Transplants
Procedure
Lead sponsor
Duke University
Other
Eligibility
14 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 11, 2026, 4:30 PM EDT
Terminated Phase 3 Interventional Results available

Albumin in Acute Ischemic Stroke Trial

NCT00235495
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Albumin, Saline
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 83 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
69
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 11, 2026, 4:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)

NCT05580601
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
CIML-NK Cells
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 11, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT00220740
View directory record Official record
Conditions
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Sep 11, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Results available

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

NCT05239182
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
9-ING-41, Retifanlimab, Gemcitabine, Abraxane
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Fairway, Kansas • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 11, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)

NCT01446016
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Paclitaxel, Docetaxel, Abraxane, Ixabepilone
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced Sep 11, 2026, 4:30 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

NCT03387085
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, SBRT
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 11, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus

NCT00798915
View directory record Official record
Conditions
Diabetes
Interventions
Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Sep 11, 2026, 4:30 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

hCT-MSCs for COVID19 ARDS

NCT04399889
View directory record Official record
Conditions
COVID, Corona Virus Infection, COVID19
Interventions
Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo
Biological · Other
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 11, 2026, 4:30 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.080: NANT Pancreatic Cancer Vaccine

NCT03586869
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Aldoxorubicin HCl, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Oxaliplatin, Avelumab, SBRT
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 11, 2026, 4:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

NCT02620865
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
Aldesleukin, Antibody Therapy, Fluorouracil, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Oxaliplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Sargramostim
Biological · Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 11, 2026, 4:30 PM EDT